The advantage of dual PPARα/γ agonists is, that they, in addition to the insulin-sensitizing effects of PPARγ, improve lipid parameters and reduce cardiovascular complications associated with metabolic disorders through PPARα [16,47]. The gene discussed is PPARA; the disease is Other metabolic disease.